These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15062604)

  • 1. Pulmonary hypertension as a result of drug therapy.
    Higenbottam T; Laude L; Emery C; Essener M
    Clin Chest Med; 2004 Mar; 25(1):123-31. PubMed ID: 15062604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
    Goldstein SE; Levy Y; Shoenfeld Y
    Harefuah; 1998 Dec; 135(11):489-92, 568. PubMed ID: 10911459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.
    Gross SB
    Adv Nurse Pract; 1999 Oct; 7(10):36-40. PubMed ID: 10808770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced pulmonary hypertension: must history repeat itself?
    Voelkel NF
    Pulm Pharmacol; 1996 Apr; 9(2):67-8. PubMed ID: 8880947
    [No Abstract]   [Full Text] [Related]  

  • 5. [Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].
    Wolf I; Mouallem M; Farfel Z
    Harefuah; 1998 Dec; 135(11):515-7. PubMed ID: 10911468
    [No Abstract]   [Full Text] [Related]  

  • 6. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
    McCann UD; Seiden LS; Rubin LJ; Ricaurte GA
    JAMA; 1997 Aug; 278(8):666-72. PubMed ID: 9272900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appetite suppressants and pulmonary hypertension: a long-term risk.
    Prescrire Int; 2006 Oct; 15(85):183. PubMed ID: 17131516
    [No Abstract]   [Full Text] [Related]  

  • 8. Too late, again?
    Jones NL
    Can Respir J; 2001; 8(3):127-8. PubMed ID: 11420587
    [No Abstract]   [Full Text] [Related]  

  • 9. Selections from current literature: pharmacological treatment of obesity.
    Connolly J; Verni C; Trilling J; Kelso E; Shiesha S
    Fam Pract; 1998 Feb; 15(1):88-93. PubMed ID: 9527304
    [No Abstract]   [Full Text] [Related]  

  • 10. Fenfluramine: riddle or Rosetta stone?
    Weir EK; Obreztchikova M; Hong Z
    Eur Respir J; 2008 Feb; 31(2):232-5. PubMed ID: 18238944
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anorectics and pulmonary hypertension].
    Bíbová J; Hampl V
    Cas Lek Cesk; 2000 Feb; 139(3):67-70. PubMed ID: 10838744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anorectic drugs and pulmonary hypertension from the bedside to the bench.
    Michelakis ED; Weir EK
    Am J Med Sci; 2001 Apr; 321(4):292-9. PubMed ID: 11307870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Anchors M
    Arch Intern Med; 1997 Jun; 157(11):1270. PubMed ID: 9183245
    [No Abstract]   [Full Text] [Related]  

  • 14. Fen-phen manufacturers, not physicians, are liable.
    Allen S; Henderson J
    Tex Med; 2000 May; 96(5):62-4. PubMed ID: 10843016
    [No Abstract]   [Full Text] [Related]  

  • 15. Anorexigen-related cardiopulmonary toxicity.
    Gross SB; Lepor NE
    Rev Cardiovasc Med; 2000; 1(2):80-9, 102. PubMed ID: 12457145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pulmonary hypertension and heart valve diseases induced by fenfluramine? Hypothesis or certitude? Myth or reality?].
    Godeau P; Cherin P; Tellier P
    Rev Med Interne; 1998 Oct; 19(10):700-3. PubMed ID: 9827440
    [No Abstract]   [Full Text] [Related]  

  • 17. High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine.
    Davis WM; Waters IW
    Med Hypotheses; 1997 Dec; 49(6):509-12. PubMed ID: 9466375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debate over dexfenfluramine.
    Deitel M
    CMAJ; 1997 Jul; 157(1):14, 16. PubMed ID: 9220935
    [No Abstract]   [Full Text] [Related]  

  • 20. Scientific and legal issues in fenfluramine/dexfenfluramine litigation.
    Poston WS; Foreyt JP
    Tex Med; 2000 Feb; 96(2):48-56. PubMed ID: 10723254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.